Skip to main content

Advertisement

Table 1 The characteristics of patients in each treatment arms

From: Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)

  ECF group1 TCF group2 P4
  All (n = 42) No. (%) QOL3 (n = 35) No. (%) All (n = 44) No. (%) QOL3 (n = 36) No. (%)  
Age      0.23
Mean (SD) 57. 2 (9.83) 58.1 (10.48) 55.4 (14.04) 54.2 (16.18)  
Gender      0.20
Male 34 (81) 28 (80) 31 (70) 24 (67)  
Female 8 (19) 7 (20) 13 (30) 12 (33)  
Tumor size      0.48
T2 8 (19) 8 (23) 5 (11) 5 (14)  
T3 15 (36) 12 (34) 15 (34) 11 (31)  
T4 19 (45) 15 (43) 24 (55) 20 (55)  
Lymph node      0.39
L1 20 (48) 18 (51) 14 (32) 14 (39)  
L2 17 (40) 13 (37) 20 (45) 14 (39)  
Not involvement 5 (12) 4 (12) 10 (23) 8 (22)  
Differentiation      0.30
Well differentiated 7 (17) 7 (20) 5 (11) 4 (11)  
Others 35 (83) 28 (80) 39 (89) 32 (89)  
Tumor of cardia      0.56
Yes 19 (45) 14 (40) 15 (34) 12 (33)  
Others 23 (55) 21 (60) 29 (66) 24 (67)  
Metastatic site      0.92
Liver 7 (17) 7 (20) 9 (20) 7 (20)  
Peritoneum 13 (31) 10 (29) 14 (32) 9 (25)  
Para aortic 5 (12) 4 (11) 3 (7) 3 (8)  
Multiple sites 17 (40) 14 (40) 18 (41) 17 (47)  
Primary disease      0.93
Yes 30 (71) 24 (69) 33 (75) 25 (69)  
No (recurrent) 12 (29) 11 (31) 11 (25) 11 (31)  
Response to chemotherapy      0.69
Responding (complete and partial) 17 (40) 13 (37) 18 (41) 15 (42)  
Not responding (stable or progressive disease) 25 (60) 22 (63) 26 (59) 21 (58)  
  1. 1 Epirubicin, cisplatin and 5-FU
  2. 2 Docetaxel, cisplatin and 5-FU
  3. 3 Those who completed the quality of life questionnaire
  4. 4 P values derived from t-test or chi-square analyses for comparison between two groups of patients who completed the quality of life questionnaire